Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Free Cash Flow (2020 - 2026)

Immuneering's Free Cash Flow history spans 7 years, with the latest figure at -$18.5 million for Q1 2026.

  • On a quarterly basis, Free Cash Flow fell 31.4% to -$18.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$49.9 million, a 6.96% increase, with the full-year FY2025 number at -$45.5 million, up 17.42% from a year prior.
  • Free Cash Flow came in at -$18.5 million for Q1 2026, down from -$10.0 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$9.4 million in Q2 2025, with the low at -$18.5 million in Q1 2026.
  • Historically, Free Cash Flow has averaged -$12.5 million across 5 years, with a median of -$12.0 million in 2025.
  • Biggest five-year swings in Free Cash Flow: crashed 101.35% in 2022 and later skyrocketed 31.37% in 2025.
  • Year by year, Free Cash Flow stood at -$11.8 million in 2022, then decreased by 1.08% to -$11.9 million in 2023, then decreased by 21.54% to -$14.5 million in 2024, then soared by 31.37% to -$10.0 million in 2025, then crashed by 85.79% to -$18.5 million in 2026.
  • Business Quant data shows Free Cash Flow for IMRX at -$18.5 million in Q1 2026, -$10.0 million in Q4 2025, and -$12.0 million in Q3 2025.